On April 5, 2024, 360Dx publishes an article by Justin Petrone on the annual review from the German Diagnostics Association (VDGH, Verbund ). Find it here:
The article cites a June 2023 white paper from VDGH on the current IVD (and general medical device) reform in the EU - here. That's in English.
But it looks like the press packet on the 2024 report links to several German-language documents:
These include a German 2p press release, a 23p deck, and a few JPEG bar charts.
To quote briefly from 360Dx,
While 2023 saw sales decline across the industry by more than a third to €2.3 billion ($2.1 billion), mostly because of a drop-off in SARS-CoV-2 testing, VDGH believes that the industry is undergoing changes that will set it on a path toward steady growth.
Reasons for optimism include survey data indicating that most German in vitro diagnostics manufacturers expect sales to grow this year, and three quarters of polled VDGH members said they plan to launch new tests. VDGH also believes that the increased adoption of AI, as well as digitalization efforts around healthcare in Germany, will support the development of new tests.
According to VDGH Chairman Ulrich Schmid, the industry is grappling with a number of issues, including regulatory changes, sustainability, and shortages in the labor market that could constrain future growth if unaddressed.
Personnel shortages were a high concern, while hopes for digitalization and AI grow.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.